Epidarex Capital Portfolio Company Apellis Pharmaceuticals Completes Initial Public Offering
November 14, 2017
Bethesda, Maryland, USA, and Edinburgh, UK: Epidarex Capital (“Epidarex”), an early-stage, transatlantic life science venture fund, is pleased to announce the initial public offering (“IPO”)